Identification of novel piperazine-tethered phthalazines as selective CDK1 inhibitors endowed with in vitro anticancer activity toward the pancreatic cancer.

[1]  A. Gavin,et al.  The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers , 2021, European journal of cancer.

[2]  A. Lau,et al.  Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach , 2021, EBioMedicine.

[3]  Y. Miki,et al.  CDK1 inhibitor controls G2/M phase transition and reverses DNA damage sensitivity. , 2021, Biochemical and biophysical research communications.

[4]  I. Khan,et al.  Synthetic and medicinal chemistry of phthalazines: Recent developments, opportunities and challenges. , 2020, Bioorganic chemistry.

[5]  H. Mou,et al.  The synthesis and anti-tumour properties of novel 4-substituted phthalazinones as Aurora B kinase inhibitors. , 2020, Bioorganic & medicinal chemistry letters.

[6]  J. Sangshetti,et al.  Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review. , 2019, Bioorganic & medicinal chemistry.

[7]  Saowaluk Saisomboon,et al.  Antitumor effects of flavopiridol, a cyclin-dependent kinase inhibitor, on human cholangiocarcinoma in vitro and in an in vivo xenograft model , 2019, Heliyon.

[8]  M. Noble,et al.  Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition , 2019, Cell chemical biology.

[9]  Sheridan M. Hoy.  Talazoparib: First Global Approval , 2018, Drugs.

[10]  Huan-Xiang Liu,et al.  Synthesis and biological evaluation of 2,4-disubstituted phthalazinones as Aurora kinase inhibitors. , 2018, Bioorganic & medicinal chemistry.

[11]  Olivier Michielin,et al.  SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules , 2017, Scientific Reports.

[12]  K. Amin,et al.  Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity. , 2016, European journal of medicinal chemistry.

[13]  Mamdouh M. Ali,et al.  Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives. , 2016, European journal of medicinal chemistry.

[14]  Mamdouh M. Ali,et al.  1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation. , 2016, European journal of medicinal chemistry.

[15]  R. Poon.  Cell Cycle Control: A System of Interlinking Oscillators. , 2016, Methods in molecular biology.

[16]  J. Klimeš,et al.  Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro. , 2015, Biochemical pharmacology.

[17]  R. Roskoski.  A historical overview of protein kinases and their targeted small molecule inhibitors. , 2015, Pharmacological research.

[18]  E. Deeks.  Olaparib: First Global Approval , 2015, Drugs.

[19]  H. Abdel‐Aziz,et al.  Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds. , 2014, European journal of medicinal chemistry.

[20]  Q. Guo,et al.  Synthesis and antitumor activities of novel 1,4-substituted phthalazine derivatives , 2010 .

[21]  A. Giordano,et al.  CDK inhibitors: from the bench to clinical trials. , 2010, Current drug targets.

[22]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[23]  X. Zhai,et al.  Synthesis and in vitro cytotoxicity of novel 1,4-disubstituted phthalazines , 2008 .

[24]  A. Gueiffier,et al.  Synthesis of Imidazo[2,1‐a]phthalazines, Potential Inhibitors of p38 MAP Kinase. Prediction of Binding Affinities of Protein Ligands. , 2002 .

[25]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[26]  P. Hollenberg.  Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes , 2002, Drug metabolism reviews.

[27]  Stover,et al.  New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis , 2000, Journal of medicinal chemistry.